探究门冬胰岛素30联合阿卡波糖治疗老年2型糖尿病临床价值

Exploring the Clinical Value of Insulin Aspart 30 Combined with Acarbose in the Treatment of Type 2 Diabetes in the Elderly

目的分析门冬胰岛素30联合阿卡波糖在老年2型糖尿病治疗中的应用效果。方法随机抽选2018年5月—2019年12月前来该院治疗的老年2型糖尿病患者84例,依据平行对照法分为对照组(42例,精蛋白生物合成人胰岛素联合阿卡波糖治疗)与观察组(42例,门冬胰岛素30联合阿卡波糖治疗),对血糖水平、不良反应发生状况进行对比分析。结果糖化血红蛋白、空腹血糖和餐后2 h血糖方面,治疗前,两组对比,差异无统计学意义(t=0.372、0.168、0.074,P=0.711、0.867、0.941);治疗后,观察组均比对照组低,差异有统计学意义(t=2.345、8.594、5.423,P<0.05)。不良反应发生率方面,观察组为4.76%比对照组的21.43%低,差异有统计学意义(χ^(2)=5.126,P=0.024)。结论老年2型糖尿病临床治疗过程中,联合门冬胰岛素30与阿卡波糖,不仅能够改善血糖水平,而且不良反应发生率低,值得采纳、推广。

Objective To analyze the effect of insulin aspart 30 combined with acarbose in the treatment of elderly type 2 diabetes.Methods A random selection of 84 elderly patients with type 2 diabetes who came to the hospital for treatment from May 2018 to December 2019 were divided into control groups(42 cases,protamine biosynthesis human insulin combined with acarbose)and the observation group(42 cases,insulin aspart 30 combined with acarbose treatment)according to the parallel control method,the blood glucose level and the occurrence of adverse reactions were compared and analyzed.Results In terms of glycosylated hemoglobin,fasting blood glucose and 2 h postprandial blood glucose,before treatment,the difference was not statistically significant(t=0.372,0.168,0.074,P=0.711,0.867,0.941);after treatment,the observation group was compared with the control group,the difference was statistically significant(t=2.345,8.594,5.423,P<0.05).In terms of the incidence of adverse reactions,the observation group 4.76%was lower than the control group 21.43%,the difference was statistically significant(χ^(2)=5.126,P=0.024).Conclusion In the clinical treatment of elderly type 2 diabetes,the combination of insulin aspart 30 and acarbose can not only improve blood glucose levels,but also has a low incidence of adverse reactions,which is worthy of adoption and promotion.